国际眼科纵览 ›› 2025, Vol. 49 ›› Issue (2): 115-118.doi: 10.3760/cma.j.cn115500-20240902-25206

• 综述 • 上一篇    下一篇

新型抗肿瘤靶向药物的眼毒性

张永怡  周南  齐艳华   

  1. 哈尔滨医科大学附属第二医院眼科,哈尔滨 150086
  • 收稿日期:2024-09-02 出版日期:2025-04-22 发布日期:2025-04-10
  • 通讯作者: 齐艳华,Email:qyh86605643@126.com

Ocular toxicity related to novel targeted anti-cancer agents

Zhang Yongyi, Zhou Nan, Qi Yanhua   

  1. Department of Ophthalmology, the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China
  • Received:2024-09-02 Online:2025-04-22 Published:2025-04-10
  • Contact: Qi Yanhua, Email: qyh86605643@126.com

摘要: 新型抗肿瘤靶向药物目前已经成为肿瘤治疗领域的热点之一,并为众多肿瘤患者带来了可观的治疗收益,而在其可能引发的不良事件(adverse event,AE)中,眼毒性具有起病隐匿﹑进展缓慢等特点常被忽视,影响患者的生活质量和治疗进程。常见的眼毒性包括结膜炎、角膜炎、干眼症,以及视网膜出血、视网膜脱离等。眼科医生应充分了解新型抗肿瘤靶向药物所致眼部病变的特征,积极预防和治疗,减少目标患者眼部AE发生,以提高患者的生活质量。(国际眼科纵览,2025, 49:115-118

关键词: 新型抗肿瘤药物, 眼毒性

Abstract: Targeted anti-cancer agents have now become one of the cutting-edge hotspots in the field of cancer therapy and have brought considerable therapeutic benefits to many patients. Ocular toxicity is one of the adverse events that may not be aware enough, affecting patients' living quality and treatment process. Common ocular toxicities include conjunctivitis, keratitis, dry eye, retinal hemorrhage, retinal detachment, etc. Ophthalmologists should fully acknowledge the feature of ocular toxicity caused by theses novel therapeutics, maximize the treating benefits to patients and improve life quality. (Int Rev Ophthalmol, 2025, 49:  115-118)

Key words: targeted anti-cancer agents, ocular toxicity